Aligos Therapeutics, Inc. beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.41 | $-0.14 | +90.1% | Beat |
| Q12026 FY2026 | $-2.29 | $-2.21 | +3.5% | Beat |
| Q42025 FY2025 | $-2.09 | $-1.91 | +8.6% | Beat |
Back to ALGS overview · ALGS holders · ALGS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.